RLMD News and Press, Relmada Therapeutics Inc. From 03/24/23

2023-03-24 14:28:18 ET Relmada Therapeutics ( NASDAQ: RLMD ) is making "critical changes" to a phase 3 trial of REL-1017 as an adjunct treatment for major depressive disorder. The changes are being made to the Reliance II trial, the second of two late-stage trials. ...

2023-03-23 22:27:05 ET Relmada Therapeutics, Inc. (RLMD) Q4 2022 Earnings Conference Call March 23, 2023, 04:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Maged Shenouda - CFO Cedric O'Gorman - Chief Medical Officer ...

2023-03-23 16:02:15 ET Relmada Therapeutics press release ( NASDAQ: RLMD ): FY Non-GAAP EPS of -$5.30 misses by $1.28 . As of December 31, 2022, the Company had cash, cash equivalents, and short-term investments of approximately $148.3 million, compared to cash, cash e...

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results PR Newswire CORAL GABLES, Fla. , March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addre...

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023 PR Newswire CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biote...

2023-03-15 17:27:01 ET Gainers: Telos ( TLS ) +8% . Relmada Therapeutics ( RLMD ) +7% . Enovix  ( ENVX ) +5% . Sabre  ( SABR ) +5% . Expensify ( EXFY ) +5% . Losers: LivePerson ( LPSN ) -43% . Superi...

Summary Relmada's second pivotal phase 3 trial of REL-1017 failed last December, which wasn't that surprising based on previous failure in monotherapy, RELIANCE 3. The third trial, RELIANCE 2, is ongoing, but with the recent two failures, we do not see much prospect of success. We d...

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors PR Newswire CORAL GABLES, Fla. , Jan. 12, 2023 /PRNewswire/ -- Relm...

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer PR Newswire CORAL GABLES, Fla. , Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases o...

For the second time, a phase 3 trial of Relmada Therapeutics' ( NASDAQ: RLMD ) depression candidate REL-1017 has failed . Shares are down 37% in after-hours trading. Top-line results from the RELIANCE I study showed the candidate missed its primary endpoint, statistically ...